Radioactive Drugs & PET Ligands in Development

A list of radioactive drugs & PET ligands developed/characterized by our group (drug targets in alphabetical order)

D-Amino acid oxidase (DAAO)

 

α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor with or without focusing GluA2 subunit (GluA2)

 

Anaplastic lymphoma kinase – [11C/18F]lorlatinib drug labeling

 

Autotaxin (ATX)

 

Cholesterol 24S-hydroxylase (CYP46A1)

 

Fatty acid amide hydrolase (FAAH)

 

Glycogen synthase kinase 3 (GSK3)

 

Histamine H3 receptor (H3)

 

L-Type Amino Acid Transporter (LAT1)

          under review

L-Type calcium channel

 

Leucine-rich repeat kinase 2 (LRRK2)

 

Metabotropic glutamate receptor 2 (mGluR2)

 

Metabotropic glutamate receptor 7 (mGluR7)

 

Metal binder in the brain  – copper (Cu) and Zinc (Zn) binder

 

N-Methyl D-aspartate (NMDA) receptor subtype 2B (NR2B or GluN2B)

 

Monoacylglycerol lipase (MAGL)

 

Muscarinic acetylcholine receptor subtype 4 (M4)

 

Orexin receptor 2 (OX2)

 

Phosphodiesterase 1 (PDE1)

 

Phosphodiesterase 4B (PDE4B)

          In progress

Phosphodiesterase 7 (PDE7)

 

Phosphodiesterase 10A (PDE10A)

 

Poly [ADP-ribose] polymerase 1 (PARP1)

 

Protein tyrosine kinase 7 (PTK-7) – single-stranded DNA aptamer targeted PET ligand (18F-sgc8)

 

Retinoid X receptors (RXRs) – repurposing Bexarotene for Alzheimer’s treatment

 

RNA-dependent RNA polymerase (RdRp) – pharmacokinetics study of [18F]Favipiravir in the brain

 

Single domain antibody fragments (VHHs) – click chemistry applications of anti class II MHC and anti CD11b targeted PET imaging

 

Trace amine-associated receptor subtype 1 (TAAR1)

 

Translocator protein (TSPO)

 

Transmembrane AMPAR regulatory protein (TARP) – gamma 8 subtype (TARP γ8)

 

Vasopressin receptor 1A (V1A)